1. Academic Validation
  2. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage

Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage

  • Mol Cancer Ther. 2006 Apr;5(4):885-92. doi: 10.1158/1535-7163.MCT-05-0358.
Christopher M Sturgeon 1 Zachary A Knight Kevan M Shokat Michel Roberge
Affiliations

Affiliation

  • 1 Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, British Columbia, Canada V6T 1Z3.
Abstract

In response to DNA damage, cell survival can be enhanced by activation of DNA repair mechanisms and of checkpoints that delay cell cycle progression to allow more time for DNA repair. Inhibiting both responses with drugs might cause Cancer cells to undergo cell division in the presence of lethal amounts of unrepaired DNA. However, we show that interfering with DNA repair via inhibition of DNA-dependent protein kinase (DNA-PK) reduces the ability of checkpoint inhibitors to abrogate G2 arrest and their radiosensitizing activity. Cells exposed to the DNA-PK Inhibitor AMA37, DNA-PK-deficient cells, and nonhomologous end joining-deficient cells all enter prolonged G2 arrest after exposure to ionizing radiation doses as low as 2 Gy. The checkpoint kinase Chk2 becomes rapidly and transiently overactivated, whereas Chk1 shows sustained overactivation that parallels the prolonged accumulation of cells in G2. Therefore, in irradiated cells, DNA repair inhibition elicits abnormally strong checkpoint signaling that causes essentially irreversible G2 arrest and strongly reduces the ability of checkpoint kinase inhibitors to overcome G2 arrest and radiosensitize cells. Variable levels of proteins controlling DNA repair have been documented in Cancer cells. Therefore, these results have relevance to the development of DNA-PK inhibitors and G2 checkpoint inhibitors as experimental therapeutic approaches to enhance the selective killing of tumor cells by radiotherapy or DNA-damaging chemotherapeutic agents.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100706
    99.48%, DNA-PK 抑制剂